RECSI in a positive trendRECSI is in a very bullish trend above 10, 20 and 50 MA on daily. Breakout above 100 MA and out of that falling bullish wedge can be explosive.
Scatec Long position I see a high upside potential, both from a fundamental side of the company and through a technical point of view. Interesting company and sector to keep a close eye on.
TOMRA bryder sin RANGE ? 📊🤷♂️Jeg er ikke inde i denne aktie, men har blot lavet denne fordi der var en i gruppen der spurgte ind til den.
Husk altid at handle ud fra dine egne signaler!
Mon den bliver over ?
Storebrand ASAShare back above pivot and EMA cloud.
Current: 82.74
Stop: 79.40
Long target is the possible gap close around 86.40 as well as swing highs near 88.62.
Storebrand is a financial services company in Norway. By volume, the company's main activities are related to life insurance and pension savings.
big buy opportunitie (high risk): NAS gets green lightThe High Court of Ireland and Oslo Byfogdembete approved the Norwegian Air Shuttle proposed scheme of arrangement to exit the bankruptcy protection in Ireland and Norway.
source: www.aerotime.aero
ArcticZymes Technologi $AZT - Oslo børsPossible retest of broken ascending triangel. And coould head for 128kroner.
ELKEM ASAThis is a very simple pattern that happens now, when the price is in the channel and RSI around 30. I expect a profitable long postion. (Disclaimer: Plesae do your analysis and do not follow me, I am not a profesional trader.)
Ultimovacs ASCO 2021 60% ORR 30% CR #cancervaccineUltimovacs’ UV1 in combination with pembrolizumab shows 60% Objective Response Rate in advanced melanoma Phase I data
• UV1/pembrolizumab results in 30% complete responses plus 30% partial responses
• Good safety and tolerability profile supports use of UV1 in combination treatments
• Data to be presented at ASCO and abstract to be discussed in webcast on May 20, 2021
Oslo, 19 May 2021: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced that its universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab, demonstrated a 60% objective response rate (ORR) in metastatic malignant melanoma. All patients have been observed for at least 18 months and median observation time is 21 months. The results will be presented as an online poster at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.
The 60% ORR (6 complete responses (CR); 6 partial responses (PR) from a 20-patient cohort) with 30% CR, clearly exceeds the response rate for pembrolizumab alone in advanced melanoma (33-37% ORR and 5-12% CR)*. The median progression-free survival for the UV1/pembrolizumab combination in the study was 18.9 months compared with 5.5-11.6 months* for pembrolizumab alone in advanced melanoma. The overall survival was 80%, with the median overall survival yet to be reached after 21-months of follow-up.
“These very strong and exciting data further strengthen the foundation for our broad Phase II clinical program for UV1,” said Jens Bjørheim, Chief Medical Officer at Ultimovacs. “To show this level of beneficial clinical response while being safe and well-tolerated in combination with pembrolizumab underscores our development strategy to show that UV1 can provide a significant increase in therapeutic effect in a broad range of indications and combinations.”
The rationale for the use of UV1 is that patients with advanced malignant melanoma often lack the relevant T cells to obtain durable benefits from the use of pembrolizumab alone. UV1 expands T cells that have the potential to increase the breadth and diversity of the immune response towards all parts of the tumor.
The data comes from Ultimovacs’ open-label Phase I study (NCT03538314) and will be shown as a poster presentation at ASCO, to be held virtually Friday, June 4, 2021 through Tuesday, June 8, 2021. The data also shows that the UV1/pembrolizumab combination is well tolerated, with adverse events largely restricted to low grade effects, mainly injection site reactions.
“These data reinforce our conviction that UV1 can play a transformative role in the treatment of conditions such as malignant melanoma,” said Carlos de Sousa, CEO of Ultimovacs. “It suggests that UV1 in combination with checkpoint inhibitors like pembrolizumab can mobilize the immune system to fight cancer. This is very encouraging for melanoma patients and for those involved with the roll-out of Ultimovacs’ broader programs in solid cancers.”
Webcast
A corporate webcast will be held on Thursday 20 May 2021, 10:00 CEST. Carlos de Sousa, CEO of Ultimovacs and Jens Bjørheim, CMO, will discuss the ASCO abstract. It will be possible to submit written questions during the presentation. The webcast will be available subsequently on the company website;
Buying Elkem StocksElkem Stocks in a bullish move and had in the last weeks a little sellof, so it can now be bought on the lower trend channel, with a good change risk profile.
Elkem producing wafers, which are essential "raw material" for the semiconductor industry.
Quantafuel longIf you believe in the company and use the analysis made by Sparbank which has a target of 200NOK based on 6 operational facilities by 2023. (Search "sparebank 1 markets quantafuel" to find the report.)
It is some of roller coaster being long in this company. But the fundamentals has not changed, we are still getting positive news from the company and there is a huge potential. Invest with care!
KOA out of long-term downtrend Seems like it's finally broken out of the long term downtrend it's been in since 2018.
Personally in pretty heavy, let's see how it plays out.
$KAHOT, CAOTIC MOVEMENTS, VALUATION +++Observing this one;
Earnings mvmnt trend, equaling caos.
May jump into the cut
Zaptec Bullish Movestrong Q1 financials, we can possibly see earlier or new highs next month or so. Be careful og strong resistances on the way up. (NOT FINANCIAL ADVICE)
